Plasma proteomics identifies an IL-6 -associated SAA axis linked to muscle wasting and survival in patients with cancer cachexia
- 1Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Abstract
Cachexia affects nearly half of patients with lung- and pancreatic cancer and worsens prognosis, yet factors driving muscle wasting remain poorly defined. We performed longitudinal clinical and plasma proteomic profiling of 67 patients with non-small cell lung cancer, with and without cachexia, during first-line treatment. At diagnosis, cachectic patients showed 128 upregulated and 67 downregulated plasma proteins relative to non-cachectic patients. Longitudinal body composition, physical performance, clinical outcome, and nutritional risk assessments revealed distinct fat- and muscle-wasting trajectories: 71 proteins tracked with fat loss, 92 with muscle loss, and 177 with concurrent muscle and weight loss. Patients with concurrent loss had 68% shorter median overall survival than those who preserved mass (239 vs. 740 days). Among proteins associated with both muscle loss and adverse outcomes, we prioritized eight candidates and screened their recombinant forms, where serum amyloid A (SAA) produced a 47% reduction in myotube width and impaired contractile function in human 2D and 3D myotubes. In an independent cohort of 146 patients with advanced pancreatic cancer, pharmacological blockade of IL-6 signaling with tocilizumab normalized circulating SAA levels, establishing a cancer-driven IL-6-SAA axis that promotes muscle wasting. In both lung and pancreatic cancer, elevated SAA was associated with reduced overall survival. Together, these findings identify SAA1 and SAA2 as IL-6-driven, cachexia-associated factors that impair muscle mass and function and predict survival, nominating the IL-6-SAA axis as a therapeutic target for cancer cachexia.
Related
- Plasma proteomics identifies an endoplasmic reticulum stress-associated molecular signature across cardiovascular-kidney-metabolic syndrome stages
- Large-scale plasma proteomics identifies proteins and pathways associated with incident interstitial lung disease
- Synaptic proteomics identifies cathepsin B as a regulator of synapse remodelling during learning
- Neurokinin 1 receptor blockade is associated with increased survival of patients with C. difficile infection
- Large-scale cerebrospinal fluid proteomics identifies diagnostic biomarker candidates across the clinico-pathological continuum of frontotemporal lobar degeneration
BibTeX
@misc{sorensen2026plasma,
title = {{Plasma proteomics identifies an IL-6 -associated SAA axis linked to muscle wasting and survival in patients with cancer cachexia}},
author = {J. Sorensen and C. T. Voldstedlund and Z. K. J. Ogueboule and J. Modvig and C. Knos and A. Hammershoi and C. S. Carl and C. B. Lindqvist and E. Battey and A. Irazoki and S. H. Raun and M. S. Ali and E. Frank and A. Bigot and J. Christensen and C. Suetta and N. J. W. Albrechtsen and E. A. Richter and J. S. Johansen and G. P. Kurita and S. W. Langer and I. M. Chen and L. Sylow},
howpublished = {bioRxiv},
year = {2026},
month = jun,
doi = {10.64898/2026.06.11.730788},
url = {https://www.biorxiv.org/content/10.64898/2026.06.11.730788v2},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Plasma proteomics identifies an IL-6 -associated SAA axis linked to muscle wasting and survival in patients with cancer cachexia
AU - J. Sorensen
AU - C. T. Voldstedlund
AU - Z. K. J. Ogueboule
AU - J. Modvig
AU - C. Knos
AU - A. Hammershoi
AU - C. S. Carl
AU - C. B. Lindqvist
AU - E. Battey
AU - A. Irazoki
AU - S. H. Raun
AU - M. S. Ali
AU - E. Frank
AU - A. Bigot
AU - J. Christensen
AU - C. Suetta
AU - N. J. W. Albrechtsen
AU - E. A. Richter
AU - J. S. Johansen
AU - G. P. Kurita
AU - S. W. Langer
AU - I. M. Chen
AU - L. Sylow
PY - 2026
DA - 2026/06/11
PB - bioRxiv
DO - 10.64898/2026.06.11.730788
UR - https://www.biorxiv.org/content/10.64898/2026.06.11.730788v2
AB - Cachexia affects nearly half of patients with lung- and pancreatic cancer and worsens prognosis, yet factors driving muscle wasting remain poorly defined. We performed longitudinal clinical and plasma proteomic profiling of 67 patients with non-small cell lung cancer, with and without cachexia, during first-line treatment. At diagnosis, cachectic patients showed 128 upregulated and 67 downregulated plasma proteins relative to non-cachectic patients. Longitudinal body composition, physical performance, clinical outcome, and nutritional risk assessments revealed distinct fat- and muscle-wasting trajectories: 71 proteins tracked with fat loss, 92 with muscle loss, and 177 with concurrent muscle and weight loss. Patients with concurrent loss had 68% shorter median overall survival than those who preserved mass (239 vs. 740 days). Among proteins associated with both muscle loss and adverse outcomes, we prioritized eight candidates and screened their recombinant forms, where serum amyloid A (SAA) produced a 47% reduction in myotube width and impaired contractile function in human 2D and 3D myotubes. In an independent cohort of 146 patients with advanced pancreatic cancer, pharmacological blockade of IL-6 signaling with tocilizumab normalized circulating SAA levels, establishing a cancer-driven IL-6-SAA axis that promotes muscle wasting. In both lung and pancreatic cancer, elevated SAA was associated with reduced overall survival. Together, these findings identify SAA1 and SAA2 as IL-6-driven, cachexia-associated factors that impair muscle mass and function and predict survival, nominating the IL-6-SAA axis as a therapeutic target for cancer cachexia.
ER -